What is the appropriate management and workup for a patient with acute left brachial artery occlusion causing critical limb ischemia, who has a history of bilateral pulmonary emboli and deep vein thromboses, is on chronic warfarin with missed doses, and has risk factors of tobacco use and hormone replacement therapy?

Immediate Management of Acute Left Brachial Artery Occlusion with Critical Limb Ischemia

This patient requires urgent surgical revascularization within hours, immediate systemic anticoagulation with unfractionated heparin (unless contraindicated by active bleeding), and comprehensive workup to determine the embolic source and prevent recurrence.

Immediate Actions (Within Hours)

1. Anticoagulation - Start NOW

Initiate therapeutic unfractionated heparin immediately unless active bleeding is present 1. Given her subtherapeutic anticoagulation from missed warfarin doses, this is critical to prevent thrombus propagation and facilitate revascularization 1, 2.

• Bolus: 80 IU/kg IV (or 5,000-10,000 IU standard dose)
• Infusion: 18 IU/kg/hour (or 1,300 IU/hour standard)
• Target: APTT 1.5-2.5 times control (45-75 seconds)
• Monitor: APTT at 4-6 hours after bolus, then 6-10 hours after any dose change 3

Critical pitfall: Do NOT delay heparin while arranging imaging or surgery. The anticoagulation should begin at diagnosis 1.

2. Urgent Revascularization

Proceed to revascularization within hours given the presence of critical limb ischemia with paresthesia (indicating neurological deficit) 4. The patient has a threatened but salvageable limb (Rutherford IIa or IIb).

Surgical options based on recent evidence:

• Brachial thromboembolectomy via open approach is the most established method 5, 6
• Consider percutaneous aspiration thromboembolectomy (PAT) via transbrachial approach - highly effective for upper extremity embolic occlusions with complete resolution in recent case series 7
• Hybrid approach: If residual thrombus after initial intervention, transbrachial PAT can be performed as salvage 8, 7

3. Monitor for Compartment Syndrome

Assess compartment pressures immediately after revascularization and maintain high vigilance for 24-48 hours 1. Given the acute presentation with paresthesia, she is at elevated risk for reperfusion injury.

• Perform prophylactic fasciotomy if prolonged ischemia (>6 hours), severe tissue ischemia, or elevated creatine kinase 1
• Clinical signs: tense compartments, pain out of proportion, progressive neurological deficit
• Do not delay fasciotomy if compartment syndrome develops - devastating complications include tissue necrosis, infection, and amputation 1

Comprehensive Workup

Determine Embolic Source (Critical for Preventing Recurrence)

This patient's presentation strongly suggests cardiac embolism given her history of bilateral PEs/DVTs and now arterial thromboembolism 9.

Immediate cardiac evaluation:

1. Transthoracic echocardiogram (TTE) - look for:

   • Left atrial/left atrial appendage thrombus
   • Valvular vegetations or abnormalities
   • Left ventricular thrombus
   • Patent foramen ovale (PFO) - critical given her DVT history suggesting paradoxical embolism 10

2. Transesophageal echocardiogram (TEE) if TTE non-diagnostic:

   • Superior visualization of left atrial appendage
   • Assessment for aortic arch atheroma/thrombus 9
   • PFO with bubble study

3. CT angiography of aorta and proximal vessels:

   • Evaluate for aortic arch mural thrombus (can cause systemic embolization) 9
   • Assess for proximal arterial disease or aneurysm

4. ECG and telemetry monitoring:

   • Rule out atrial fibrillation (most common cause of arterial embolism)
   • Consider extended monitoring if initial ECG normal

Reassess Hypercoagulability Workup

Despite prior negative workup, reconsider thrombophilia testing given the pattern of recurrent thrombosis in multiple vascular beds:

• Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-β2-glycoprotein I)
• Factor V Leiden and Prothrombin G20210A mutation
• Protein C, Protein S, Antithrombin levels (must be off warfarin for accurate results)
• Homocysteine level
• Consider JAK2 mutation (myeloproliferative disorders) given unusual presentation

Important: The combination of venous AND arterial thrombosis is unusual and warrants investigation for antiphospholipid syndrome or paradoxical embolism through cardiac shunt 10.

Long-Term Anticoagulation Strategy

Bridging from Heparin to Warfarin

Resume warfarin immediately once bleeding risk is acceptable post-procedure 2:

• Initial dose: 5 mg daily (lower than standard 5-10 mg given her prior therapeutic dose and recent non-compliance) 3, 2
• Overlap heparin and warfarin for minimum 5 days AND until INR ≥2.0 for 24 hours 3, 2
• Target INR: 2.5 (range 2.0-3.0) 2
• Monitor INR: Daily initially, then every 1-2 days until stable 3, 2

Duration of Anticoagulation

Indefinite anticoagulation is indicated given 2:

• Recurrent thrombotic events (bilateral PEs, DVTs, now arterial thrombosis)
• Likely idiopathic or related to persistent risk factors
• History of life-threatening events

Critical counseling points 2:

• Strict adherence to daily dosing - missed doses led to this catastrophic event
• Avoid NSAIDs, aspirin (unless specifically indicated), alcohol
• Maintain consistent vitamin K intake
• Avoid cranberry products
• Immediate reporting of bleeding signs
• Discontinue hormone replacement therapy - this is a modifiable thrombotic risk factor 3

Alternative Anticoagulation Considerations

While warfarin is appropriate, consider direct oral anticoagulants (DOACs) if:

• Continued non-adherence with warfarin monitoring
• Difficulty maintaining therapeutic INR
• Patient preference for fixed dosing

However, warfarin may be preferable in this high-risk patient because:

• Allows precise dose titration and monitoring
• Reversible with vitamin K or PCC if bleeding occurs
• Better studied in complex thrombotic syndromes
• Recent case report suggests warfarin superiority in high-risk embolic patients 11

Risk Factor Modification

Mandatory interventions:

1. Tobacco cessation - absolute requirement given her thrombotic history
2. Discontinue hormone replacement therapy - significant thrombotic risk factor 3
3. Optimize cardiovascular risk factors (blood pressure, lipids)

Follow-Up Protocol

Short-term (first 3 months):

• Weekly INR monitoring until stable, then every 2-4 weeks
• Vascular surgery follow-up at 2 weeks, 6 weeks, 3 months
• Assess limb perfusion, neurological function, wound healing
• Repeat imaging (duplex ultrasound) at 6 weeks to confirm patency

Long-term:

• INR monitoring every 4 weeks when stable
• Annual vascular assessment
• Cardiology follow-up if cardiac source identified
• Consider anticoagulation clinic referral for improved therapeutic time in range 2

Reassess at 6-12 weeks 3:

• If cardiac source identified and treated, continue indefinite anticoagulation
• If paradoxical embolism through PFO, consider PFO closure plus anticoagulation
• If recurrent idiopathic events, strongly consider indefinite therapy 2